Prucalopride

Generic Name
Prucalopride
Brand Names
Motegrity, Resolor, Resotran
Drug Type
Small Molecule
Chemical Formula
C18H26ClN3O3
CAS Number
179474-81-8
Unique Ingredient Identifier
0A09IUW5TP
Background

Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. Prucalopride...

Indication

Prucalopride is indicated for the treatment of chronic idiopathic constipation (CIC) in adults.

CIC is one of the most common chronic functional gastrointestinal disorders worldwide. The diagnosis of this agent is very hard and it can be confirmed if the patient experience at least two of the following:
...

Associated Conditions
Opioid Induced Constipation (OIC), Chronic idiopathic constipation (CIC), Refractory Chronic idiopathic constipation
Associated Therapies
-
Clinical Trials
Related News

Prucalopride Versus Placebo in Gastroparesis

First Posted Date
2014-01-09
Last Posted Date
2020-10-08
Lead Sponsor
University of Calgary
Target Recruit Count
15
Registration Number
NCT02031081
Locations
🇨🇦

University of Calgary, Calgary, Alberta, Canada

Prucalopride for Postoperative Ileus in Patients Undergoing Gastrointestinal Surgery

Phase 2
Completed
Conditions
Postoperative Ileus
Interventions
Drug: Placebo
Drug: Prucalopride
First Posted Date
2013-12-09
Last Posted Date
2016-09-30
Lead Sponsor
Jinling Hospital, China
Target Recruit Count
110
Registration Number
NCT02004652
Locations
🇨🇳

Department of Generay Surgery, Jinling hosptal, Medical School of Nanjing University, Nanjing, Jiangsu, China

Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of YH12852 After Oral Administration in Healthy Male Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
Drug: YH12852
Drug: Prucalopride
First Posted Date
2013-06-06
Last Posted Date
2015-05-08
Lead Sponsor
Yuhan Corporation
Target Recruit Count
127
Registration Number
NCT01870674
Locations
🇰🇷

Inje Busan Paik hospital, Busan, Korea, Republic of

The Colonic Transit Time: a Modifiable Determinant of Intestinal Production and Uptake of Microbial Metabolites?

Withdrawn
Conditions
Constipation
Interventions
Drug: Prucalopride
First Posted Date
2013-06-05
Last Posted Date
2020-04-24
Lead Sponsor
Universitaire Ziekenhuizen KU Leuven
Registration Number
NCT01869751
Locations
🇧🇪

University Hospitals Leuven, Leuven, Vlaams-Brabant, Belgium

Prucalopride + Prucalopride Booster vs. Prucalopride + Picosalax Booster for the Colon Capsule

First Posted Date
2013-05-30
Last Posted Date
2017-02-16
Lead Sponsor
Queen's University
Target Recruit Count
60
Registration Number
NCT01864915
Locations
🇨🇦

Hotel Dieu Hospital, Kingston, Ontario, Canada

Study to Investigate Prucalopride vs. Polyethylene Glycol 3350 on Colon Activity

Phase 4
Completed
Conditions
Chronic Constipation
Interventions
Drug: prucalopride
Drug: PEG 3350
First Posted Date
2012-10-16
Last Posted Date
2021-07-02
Lead Sponsor
Shire
Target Recruit Count
13
Registration Number
NCT01707667
Locations
🇧🇪

UNIVERSITY OF LEUVEN, UNVERSITY HOSPITAL, Gasthuisberg, Leuven, Belgium

🇺🇸

Oklahoma Foundation for Digestive Research, Oklahoma City, Oklahoma, United States

🇬🇧

Barts Health NHS Trust, Whitechapel, London, United Kingdom

A Post Marketing Surveillance Study on the Safety and Effectiveness of Prucalopride in the Treatment of Chronic Constipation

Withdrawn
Conditions
Chronic Constipation
Interventions
Drug: Prucalopride
First Posted Date
2012-09-25
Last Posted Date
2015-12-02
Lead Sponsor
Janssen Pharmaceutica
Registration Number
NCT01692132

Single Dose Pharmacokinetics of Prucalopride in Paediatric Subjects, With Functional Faecal Retention

Phase 1
Completed
Conditions
Constipation
Interventions
Drug: prucalopride
First Posted Date
2012-08-28
Last Posted Date
2012-08-28
Lead Sponsor
Movetis
Target Recruit Count
38
Registration Number
NCT01674166

Prucalopride Subjects With Renal Impairment

Phase 1
Completed
Conditions
Constipation
Interventions
Drug: prucalopride
First Posted Date
2012-08-28
Last Posted Date
2012-08-28
Lead Sponsor
Movetis
Target Recruit Count
34
Registration Number
NCT01674192

Prucalopride in Paediatric Subjects, With Functional Faecal Retention

Phase 1
Completed
Conditions
Constipation
Interventions
Drug: prucalopride
First Posted Date
2012-08-22
Last Posted Date
2012-08-22
Lead Sponsor
Movetis
Target Recruit Count
37
Registration Number
NCT01670669
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy